# MTX240

Source: https://onco.cc/drugs/mtx240/  
OnCo record `mtx240` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MTX240 is an early drug from Biodexa Pharmaceuticals for gastrointestinal stromal tumour that kills tumour cells by a route that does not depend on the KIT protein, which matters once standard tablets stop working.

## Summary

MTX240, formerly OPB-171775, was licensed by Biodexa Pharmaceuticals from Otsuka in February 2026. Otsuka assembled a preclinical package and obtained approval for a phase 1 study from Japan's PMDA. Biodexa's first priorities are clinical trial manufacturing, an IND filing and a phase 1b/2a dose-escalation study in GIST, including tumours resistant to tyrosine kinase inhibitors.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-04
- Also known as: OPB-171775
- Tags: pipeline
- Code: MTX240
- Modality: Small-molecule molecular glue
- Mechanism: A molecular glue that brings together PDE3A and SLFN12, co-expressed in GIST cells, stabilising SLFN12 so that it drives RNase-mediated cell death independently of KIT signalling, as described by Biodexa Pharmaceuticals.

## Sources

- SEC: Biodexa Pharmaceuticals Form F-1, September 2026: https://www.sec.gov/Archives/edgar/data/1643918/000121465926011934/y917262f1.htm

## Connected records

- technologies: [Molecular glue discovery platforms](https://onco.cc/technologies/molecular-glue-platforms/)
- companies: [Biodexa Pharmaceuticals](https://onco.cc/companies/biodexa-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/mtx240.json